Werewolf Therapeutics Operating Income Over Time
| HOWL Stock | USD 0.63 0.01 1.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Werewolf Therapeutics Performance and Werewolf Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Werewolf Therapeutics and related stocks such as IO Biotech, Spruce Biosciences Common, and OUTLOOK THERAPEUTICS INC Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOBT | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (10.1 M) | (41.2 M) | (71.4 M) | (91.4 M) | (95.2 M) | (85.7 M) | (81.4 M) |
| SPRB | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (13.1 M) | (29.4 M) | (42.1 M) | (47.3 M) | (52 M) | (56.2 M) | (50.5 M) | (53.1 M) |
| OTLK | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (46.6 M) | (51.3 M) | (35.9 M) | (29.6 M) | (36.3 M) | (36.8 M) | (51.7 M) | (63.1 M) | (53.1 M) | (71.7 M) | (67.1 M) | (60.4 M) | (63.4 M) |
| ACET | 21.4 M | 16.6 M | 25.4 M | 34.4 M | 34.4 M | 44.3 M | (1000) | (18.9 M) | (15 M) | (31.4 M) | (39.2 M) | (61.4 M) | (72.6 M) | (152 M) | (127.6 M) | (114.9 M) | (109.1 M) |
| NRXP | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (1 M) | (713.2 K) | (22.1 M) | (95.2 M) | (44.3 M) | (27.6 M) | (19.7 M) | (17.7 M) | (18.6 M) |
| LITS | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (75.5 M) | (36.8 M) | 14.5 M | (17.5 M) | (20.1 M) | (21.1 M) |
| OSTX | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (4.8 M) | (4.4 M) | (4.3 M) | (6.8 M) | (6.1 M) | (6.4 M) |
| CUE | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (7.7 M) | (23.2 M) | (38.7 M) | (36.8 M) | (45 M) | (43.7 M) | (53.2 M) | (52.1 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (227 K) | (981 K) | (12.4 M) | (7.8 M) | (12.2 M) | (29.2 M) | (26 M) | (29.7 M) | (42.6 M) | (38.4 M) | (36.5 M) |
Werewolf Therapeutics and related stocks such as IO Biotech, Spruce Biosciences Common, and OUTLOOK THERAPEUTICS INC Operating Income description
Operating Income is the amount of profit realized from Werewolf Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Werewolf Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Werewolf Therapeutics | HOWL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 200 Talcott Ave, |
| Exchange | NASDAQ Exchange |
USD 0.63
Check out Werewolf Therapeutics Performance and Werewolf Therapeutics Correlation. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Werewolf Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.